Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.55 |
| ▸ | MME | P08473 | 3/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP14 | P50281 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | GRN | P28799 | 1/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8249122 | 1.00 | FOLH1 (0.55) | FOLH1MMELTA4HANPEPMMP9 | |
| SCHEMBL5869744 | 1.00 | FOLH1 (0.55) | FOLH1MMELTA4HANPEPMMP9 | |
| SCHEMBL8248672 | 1.00 | FOLH1 (0.55) | FOLH1MMELTA4HANPEPMMP9 | |
| SCHEMBL12861495 | 0.87 | CTSS (0.53) | FOLH1MMELTA4HANPEPCTSL | |
| SCHEMBL17530041 | 0.85 | MMP9 (0.55) | MMEMMP9MMP14MMP1MMP3 | |
| SCHEMBL18722285 | 0.85 | MMP9 (0.55) | MMEMMP9MMP14MMP1MMP3 | |
| SCHEMBL17530042 | 0.85 | MMP9 (0.55) | MMEMMP9MMP14MMP1MMP3 | |
| SCHEMBL8248701 | 0.84 | FOLH1 (0.47) | FOLH1MMP9MMP1MMP3GRN | |
| SCHEMBL5869900 | 0.84 | FOLH1 (0.47) | FOLH1MMP9MMP1MMP3GRN | |
| SCHEMBL5869765 | 0.83 | FOLH1 (0.52) | FOLH1ANPEPCTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | FOLH1 229/4885MME 11/4885LTA4H 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.